Utility of Short-Acting Intravenous Insulin Therapy in Preparation of F-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography Scan in Cancer Patients Incidentally Detected with High Blood Glucose Levels on the Day of Test

Abstract

Background: In diabetic (DM) patients, hyperglycemia degrades image quality in F-18 FDG PET CT by altering bio-distribution of FDG in the body and augmenting soft tissue and muscular uptake. We intend to evaluate the use of short acting IV insulin in minimising the rescheduling of patients detected with FBG>160 mg/dL on the day of scan. Aim and Objectives: To show the utility of short acting IV insulin therapy in preparation of cancer patients incidentally detected with high blood glucose levels for F-18 FDG PET CT scan, (>160mg/dL) and to compare the obtained image quality with patients detected with fasting blood glucose level (FBG) <100mg/dL and <160 mg/dL, using visual and semi quantitative methods. Material and Methods: 613 cancer patients referred for PET CT were divided into 3 groups, Group I (n=30): known diabetics (DM) or incidentally diagnosed with FBG >160 mg/dL, Group II (n=349): DM patients with FBG <160 mg/dL (100-160mg/dL), Group III (n=234): Non DM patients FBG <100mg/dL. In Group I short acting insulin was given intravenously using a sliding scale, post insulin after 90 minutes F-18 FDG (radiotracer) injection was given and PETCT scan was obtained 60 mins post radiotracer injection. Qualitative image analysis was done using biodistribution score and quantitative analysis was done by chi square test, ANOVA (analysis of variance) and paired t-test. Results: In group I patients post insulin there was significant decrease in FBG levels (216±22.2 to 136±13.4mg/dL) and acceptable image quality. Comparison of quantitative parameters (mean and maximum SUV calculated by drawing ROI around heart, liver, muscle, subcutaneous fat) among the 3 groups showed significant intergroup difference with p value <0.05. Conclusion: This short acting IV insulin protocol is safe and can be used to obtain optimal quality F-18 FDG PET CT scan images by alleviating the need for rescheduling patients though they present with high glucose levels.

Keywords: Cancer, diabetes mellitus, F-18 fluorodeoxyglucose positron emission tomography computed tomography, hyperglycemia, intravenous insulin

Introduction

F-18 fluoro-deoxyglucose (FDG) is a time-tested molecular imaging radiopharmaceutical used in positron emission tomography computed tomography (PET CT) imaging with many applications in the field of oncology such as cancer staging, evaluation of unknown primary cancer, treatment response, and recurrence evaluation. [1] PET CT scan with F-18 FDG is technically demanding protocol-based test, as the image quality may be influenced by various factors such as physical exercise, brown fat activation, hyperglycemia, hyperinsulinemia, inflammation, and thyrotoxicosis. [2,3]

In diabetes mellitus (DM) patients, plasma glucose levels and serum insulin levels will affect the biodistribution of F-18 FDG. Increased glucose levels decrease the F-18 FDG uptake in the tumors because F-18 FDG and glucose compete for glucose transport and phosphorylation by hexokinase. Hyperinsulinemia in response to elevated blood glucose causes rapid shunting of F-18 FDG to organs with high density of insulin receptors (e.g., skeletal and cardiac muscles) by increased translocation of glucose transporter-4 (GLUT4), thereby resulting in altered radiotracer biodistribution and

Address for correspondence:
Dr. Tekchand Kalawat,
Department of Nuclear Medicine, SVIMS, Tirupati, Andhra Pradesh, India
E-mail: kalawat.svims@gmail.com
Received: 20-08-2019
Accepted: 30-08-2019
Published: 12-03-2020.

How to cite this article: Rallapeta, Ranadheer Gupta Manthri, Tekchand Kalawat, Alok Sachan, A Y Lakshmi, Narendra Hulikal. Utility of short-acting intravenous insulin therapy in preparation of F-18 fluorodeoxyglucose positron emission tomography computed tomography scan in cancer patients incidentally detected with high blood glucose levels on the day of test. Indian J Nucl Med 2020;35:110-5.
suboptimal image quality. Therefore, preparation of DM patients with cancer requires more meticulous care, as some patients may report with high blood glucose levels on the day of test.

F-18 FDG PET CT scan is usually performed following the procedure guidelines prescribed by the European Association of Nuclear Medicine and Molecular Imaging and Society of Nuclear Medicine. It is ideal to reschedule the patients for PET CT scan during conditions of hyperglycemia and hyperinsulinemia; however, rescheduling delays the diagnosis and also adds on to the financial burden of the center. In literature, to overcome these, some alternative methods using various insulin protocols have been proposed to prepare the patient.

The use of insulin lowers fasting blood glucose (FBG) levels in DM patients presenting with hyperglycemia; however, if F-18 FDG injection was given before the complete physiological neutralization of insulin, it may cause suboptimal image quality with uptake in muscles and soft tissue. Therefore, the present study was designed to use short-acting intravenous (IV) insulin to lower hyperglycemia, and timing of F-18 FDG injection was delayed to 90 min, postinsulin therapy to obtain the optimal image quality.

Materials and Methods

Ethics approval was obtained from the Institutional Ethics Committee.

Study design

The design was a prospective interventional study.

Study population

A total of 613 patients referred for F-18 FDG whole-body PET CT scan who met the inclusion criteria were prospectively studied. Written informed consent was obtained from all patients. FBG levels were estimated, and patients were divided into three groups, namely Group I: DM patients with FBG >160 mg/dL (known diabetics or incidentally diagnosed), Group II: DM patients with FBG <160 mg/dL (100–160 mg/dL), and Group III: nondiabetic patients with normal FBG (<100 mg/dL).

Patient preparation and insulin administration

All patients in Group I were given short-acting IV insulin (injection human insulin 40 IU/mL) diluted in 10 mL normal saline, using a sliding scale. Patients with FBG >280 mg/dL were excluded from the study. Postinsulin therapy blood glucose monitoring was done at every 30 min till 90 min, and all precautions were taken to treat patients with hypoglycemia. All patients in three groups were given 370 MBq (10 mCi) of F-18 FDG through IV cannula. Group I patients received F-18 FDG injection after 90 min of insulin therapy. In all other patients (Groups II and III), scan was acquired 60 min post F-18 FDG injection.

Acquisition protocol and image analysis

Images were obtained in caudocranial orientation of supine position, covering body from thigh to vertex on a dedicated Siemens PET CT scanner (Biograph-06). PET CT images were analyzed visually, and FDG biodistribution was graded on a five-point scale as described earlier in similar type of the study. Quantitative F-18 FDG uptake, that is, maximum standard uptake values (max SUVs) of cerebellum, cardiac muscle, liver, skeletal muscle, and fat tissue were obtained by manually drawing

---

**Table 1: Inclusion and exclusion criteria of the study population**

| Inclusion criteria                              | Exclusion criteria                                      |
|-----------------------------------------------|--------------------------------------------------------|
| All cancer patients of either gender, age (years) >18-80 | Patients not willing to participate in the study        |
| Patients willing to participate in the study   | Inflammation, infection, or trauma in the gluteal region |
|                                              | FBG >280 mg/dL                                          |
|                                              | Pregnancy                                               |
|                                              | Nursing mothers                                         |
|                                              | Recent antiretroviral therapy (HAART)                    |
|                                              | Neuromuscular disorders                                 |

HAART: Highly active antiretroviral therapy, FBG: Fasting blood glucose

---

Figure 1: F-18 fluorodeoxyglucose positron emission tomography maximum intensity projection image (a), positron emission tomography and positron emission tomography computed tomography axial images showing representative region of interests drawn over the brain (b and c), heart (d and e), liver (f and g), muscle (h and i), and fat tissue (j and k), respectively
three-dimensional (3D) region of interest (ROI) in transaxial images [Figure 1].

**Statistical analysis**

Demographic data were represented as mean ± standard deviation (SD). To compare pre-insulin FBG and postinsulin FBG levels, paired “t” test was used. Chi-square test was used to compare the biodistribution score among three Groups. *P* < 0.05 was considered statistically significant. Mean ± SD of different variables (max SUV in various ROIs) was obtained. For comparison of variables among groups, one-way ANOVA test was used.

**Results**

Total study population was 613 patients. Characteristics of the study population are described in Table 4. In Group I, a total of 30 patients were included who had FBG levels >160 mg/dL, with mean ± SD values of 214 ± 25.1 mg/dL. Among them, 18/30 (60%) were known diabetics, and 12/30 (40%) patients were detected incidentally with high FBG levels on the day of PET CT scan.

In Group I patients, IV short-acting insulin was given according to the glycemic correction sliding scale [Table 2]. The mean glucose levels at 60 min after IV insulin decreased from 216 ± 22.2 to 136 ± 13.4 mg/dL [Table 5]; it indicates that insulin doses were adequate, and there was statistically significant decrease (*P* < 0.05 using paired *t*-test) in postinsulin glucose levels. All patients in Group I tolerated IV insulin well; none of them developed hypoglycemia.

Visual image analysis [Table 3] showed acceptable quality of PET CT images in all patients with a score of “0” or “1” based on biodistribution scores (acceptable score 0, 1, and 2 and unacceptable score “3” and “4”). In Group I patients, 15/30 showed score 0, and other 15/30 showed score 1 (acceptable image quality with mild soft-tissue uptake).

Quantitative parameters and max SUV were obtained for all patients by drawing identical 3D ROI in transaxial PET CT images as shown in Figure 1. at brain (cerebellum), heart, liver, skeletal muscle, and fat. Mean ± SD values of max SUV of different regional variables, respectively, are shown in Table 6. One-way ANOVA analysis for variables showed statistically significant intergroup difference with *P* < 0.05 [Table 6].

**Discussion**

PET CT requires meticulous patient preparation as image quality may be influenced by machinery error, patient disease status, comorbid illness such as diabetes (high FBG levels), medications, radioactivity administered, extravasation, and variation in imaging protocols."

| Table 2: Sliding scale for intravenous insulin in Group I patients |
|-----------------------------|-----------------|
| Glucose level (mg/dL)       | Insulin dose (U) |
| 160-180                     | 4               |
| 180-200                     | 6               |
| 200-220                     | 8               |
| 220-240                     | 10              |
| 240-260                     | 12              |
| >260                        | 14              |

| Table 3: Biodistribution score for visual image analysis |
|---------------------------------------------------------|
| Pattern of FDG biodistribution                          | Score |
| Normal biodistribution                                  | 0     |
| Mild muscular uptake                                    | 1     |
| Muscular uptake involving ≥1 muscle group               | 2     |
| Diffuse muscular uptake of moderate intensity            | 3     |
| Diffuse, intense muscular uptake causing nondiagnostic examination | 4     |

FDG: Fluorodeoxyglucose

| Table 4: Characteristics of study population (n=613) |
|-----------------------------------------------------|
| Patient characteristics                             | Mean ± SD, No of patients (n) |
| Age (years), mean±SD (range)                        | 55±12 (30-80)                |
| Sex<sup>a</sup>                                      |                                |
| Female                                              | 334 (55)                      |
| Male                                                | 279 (45)                      |
| Groups<sup>a</sup>                                  |                                |
| Group I                                             | 30 (5)                        |
| Known DM                                            | 18                             |
| De novo DM                                          | 12                             |
| Group II                                            | 349 (55)                      |
| Known DM                                            | 349                            |
| Group III                                           | 234 (40)                      |

<sup>a</sup>Values are represented as n. DM: Diabetes mellitus, SD: Standard deviation

| Table 5: Comparison of blood glucose levels preinsulin and postinsulin |
|----------------------------------------------------------------------|
| Preinsulin and Postinsulin FBG levels                                |
| Mean ± SD, Range                                                    |
|                                                                 |
| Preinsulin (mg/dL)                                                  |
| FBG, mean±SD                                                        |
| 216±22                                                              |
| Range                                                               |
| 182-260                                                             |
| Postinsulin (mg/dL)                                                 |
| FBG, mean±SD                                                        |
| 136±13                                                              |
| Range                                                               |
| 110-168                                                             |

SD: Standard deviation, FBG: Fasting blood glucose

short-acting insulin will have onset of action at 30–60 min. Insulin decreases FBG levels by acting through GLUT receptors. Insulin-independent GLUT receptors are GLUT 1 (red blood cell, brain, and cornea), 2 (beta cells of pancreas, liver, and small intestine), 3 (brain and placenta), and insulin dependent are GLUT
4 (skeletal muscle and fat). Insulin can be administered subcutaneous (SC) or IV routes. Administration of SC insulin causes increased muscular uptake as documented in Garcia et al.’s study. It also requires more time delay for action, multiple doses to lower FBG levels which may delay injection of F-18 FDG and scan acquisition. To perform the scan in patients with high FBG levels on the same day in a remote center away from cyclotron facility, we used short-acting IV insulin protocol.

The short-acting IV insulin therapy used in Group I patients worked well and lowered the mean ± SD blood glucose levels from 216 ± 22.2 to 136 ± 13.4 mg/dL, which was statistically significant with \( P < 0.05 \). In a similar study done by Roy et al., using short-acting IV insulin therapy, the mean ± SD blood glucose levels decreased from 234 ± 36 to 126 ± 36 mg/dL.

**Visual image analysis of positron emission tomography scan**

In Group I, 15/30 (50%) patients showed score “0,” and 15/30 (50%) patients showed score “1” with decreased blood glucose levels but values remained between 130 and 160 mg/dL, mean value (148 ± 7 mg/dL); however, there was 100% acceptable image quality in all patients. Roy et al. documented 75% of study population with acceptable image quality and 25% with altered biodistribution manifested as increased muscular uptake (unacceptable image quality). Residual physiological effect of insulin might be the reason for score “1” in visual image analysis (mild muscular uptake). In our study, F-18 FDG injection was given after a gap of 90 min of insulin therapy, and all studies were of visually acceptable quality. Figures 2, 3 and 4 shows the representative images of Group I, II and III patients with optimal image quality respectively.

SUV and related parameters in PET technology are simple and popular tools for metabolic activity quantification in cancer sites and normal tissue. To know the effect of hyperglycemia on quantitative measurements, max SUV values of the brain, heart, liver, skeletal muscle, and fat tissue were measured in all patients, and they were compared statistically between groups.

In our study, brain max SUV (6.1 ± 1.85) in Group I patients was lower than Group II and III max SUV values (8.2 ± 2.15 and 8.7 ± 2.33), and it was statistically significant with \( P < 0.05 \) [Table 6]. In Group I patients with high FBG level (>160 mg/dL) physiologically, there will be increased competition between elevated plasma glucose and F-18 FDG for carrier enzymes to enter in the brain cell. Ishizu et al. studied the impact of glucose loading on visualization of brain tumors and glioma. In their study, they observed fractional decreased F-18 FDG uptake in normal brain cortex and brain tumor causing an increment in tumor to brain cortex ratio. In our study also, we were able to identify and better delineate brain metastases in Group I patients [Figure 2].

**Table 6: Maximum standardized uptake value over different region of interests**

| ROI      | Groups | Mean of max SUV + SD | Frequency | \( P \) |
|----------|--------|----------------------|-----------|--------|
| Brain    | I      | 6.1±1.8              | 30        | 0.000  |
|          | II     | 8.2±2.1              | 349       |        |
|          | III    | 8.7±2.3              | 234       |        |
| Heart    | I      | 2.9±1.8              | 30        | 0.007  |
|          | II     | 3.7±2.9              | 349       |        |
|          | III    | 4.4±3.6              | 234       |        |
| Liver    | I      | 2.9±0.6              | 30        | 0.000  |
|          | II     | 2.8±0.7              | 349       |        |
|          | III    | 2.4±0.6              | 234       |        |
| Muscle   | I      | 1.0±0.3              | 30        | 0.001  |
|          | II     | 0.8±0.5              | 349       |        |
|          | III    | 0.6±0.2              | 234       |        |
| Fat      | I      | 0.4±0.2              | 30        | 0.001  |
|          | II     | 0.4±0.1              | 349       |        |
|          | III    | 0.3±0.1              | 234       |        |

ANOVA was used to analyze the differences between group means. Bold values were statistically significant. ANOVA: Analysis of variance, ROI: Region of interest, max SUV: maximum standardized uptake value, SD: standard deviation

In whole-body F-18 FDG, PET CT used for cancer staging nonspecific uptake in the myocardium is a common finding.
which depends on the dominance of energy substrate metabolism, glucose, or free fatty acids.\textsuperscript{[15-17]} In Group I compared to noninsulin group [Table 6], there was significant decreased heart uptake (max SUV: 2.9 ± 1.8) which was consistent with the findings of Israel \textit{et al.}, who showed that myocardial F-18 FDG uptake was significantly lower in diabetics.\textsuperscript{[19]} In addition, insulin therapy and other dietary factors may also cause rapid clearance of F-18 FDG, causing decrease in circulating radiotracer available for myocardial uptake.\textsuperscript{[19,20]}

Variations in blood glucose levels are known to affect the F-18 FDG uptake in the liver cell;\textsuperscript{[21]} physiologically, this is mediated by insulin-independent GLUT-2 transporters. In our study, there was no significant difference between max SUV values of liver among Group I and Group II patients. In Group III patients, liver max SUV values were 2.4 ± 0.6, which showed statistically significant difference from Group I and II values [Table 6]; however, values in all groups were within acceptable limits.

Glucose enters through insulin-dependent GLUT-4 receptors present in the cell wall of myocardial and striated muscle.\textsuperscript{[22,23]} In our study, we observed statistically significant mild increased muscle activity in both Group I and II max SUV (1.03 ± 0.33, 0.86 ± 0.57) [Table 6]. Our results in Group II were in accordance with Hara \textit{et al.} who reported increased muscle F-18 FDG uptake due to chronic hyperglycemia.\textsuperscript{[24]} Studies done by Kelley \textit{et al.} found that glucose phosphorylation in muscles was altered in diabetic patients and that it increased in a dose-responsive manner with insulin infusion resulting in muscular uptake.\textsuperscript{[25,26]}

During hyperglycemia, insulin lowers plasma glucose by stimulating insulin-dependent GLUT-4 receptors causing glucose uptake into skeletal muscle and adipose tissue. Hence, under insulin effect, adipose tissue also takes up F-18 FDG.\textsuperscript{[6,24]} Fat uptake in Group I (0.48 ± 0.20) and Group II (0.40 ± 0.14) was slightly higher than the value in Group III (0.37 ± 0.17) and showed significant difference [Table 6] but well within acceptable limits. Thus, our study findings are consistent with previous studies done by Roy \textit{et al.} and Garcia \textit{et al.}\textsuperscript{[6,12]}

**Conclusion**

Using short-acting intravenous insulin therapy protocol, optimal quality F-18 FDG PET CT scan images can be obtained in patients detected with hyperglycemia on the day of test. This short-acting IV insulin therapy protocol is not only safe and easy to perform but avoids potential delay in diagnostic work up and save resources.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.
References

1. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.

2. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med 2010;40:283-93.

3. Schultz C. The effect of glucose on quality of PET scan results. J Pharm Pharm 2017;4:138-41.

4. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer – A PET study. J Nucl Med 1993;34:1-6.

5. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.

6. Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 2009;50:178-83.

7. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999;341:240-6.

8. Caobelli F, Pizzocaro C, Paghera B, Guerra UP. Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing (18)F-FDG PET/CT. Nucl Med Commun 2013;34:271-5.

9. Stahl A, Ott K, Schweiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004;31:1471-8.

10. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 1999;19:61-77.

11. Joshi SR, Parikh RM, Das AK. Insulin – History, biochemistry, physiology and pharmacology. J Assoc Physicians India 2007;55 Suppl: 19-25.

12. Garcia JR, Sanchis A, Juan J, Tomas J, Domenech A, Soler M, et al. Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET/CT studies. Nucl Med Commun 2014;35:459-65.

13. Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K. Plasma glucose levels affect cerebral 18F-FDG distribution in cognitively normal subjects with diabetes. Clin Nucl Med 2016;41:e274-80.

14. Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104-9.

15. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974;36:413-59.

16. Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-D-glucose. Nucl Med Commun 2002;23:961-5.

17. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.

18. Israel O, Weiler-Sagie M, Rispler S, Bar-Shalom R, Frenkel A, Keidar Z, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med 2007;48:234-9.

19. Jeong J, Kong E, Chun K, Cho I. The impact of energy substrates, hormone level and subject-related factors on physiologic myocardial (18)F-FDG uptake in normal humans. Nucl Med Mol Imaging 2013;47:225-31.

20. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190:W151-6.

21. Choi Y, Hawkins RA, Huang SC, Brunken RC, Hoh CK, Messa C, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med 1994;35:818-23.

22. Nakatani K, Nakamoto Y, Togashi K. Risk factors for extensive skeletal muscle uptake in oncologic FDG-PET/CT for patients undergoing a 4-h fast. Nucl Med Commun 2012;33:648-55.

23. Williams KV, Price JC, Kelley DE. Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: A dose-response assessment using positron emission tomography. Diabetes 2001;50:2069-79.

24. Hara T, Higashi T, Nakamoto Y, Suga T, Saga T, Ishimori T, et al. Significance of chronic marked hyperglycemia on FDG-PET: Is it really problematic for clinical oncologic imaging? Ann Nucl Med 2009;23:657-69.

25. Kelley DE, Reilly JP, Veneman T, Mandarino LJ. Effects of insulin on skeletal muscle glucose storage, oxidation, and glycolysis in humans. Am J Physiol 1990;258:E923-9.

26. Kelley DE, Williams KV, Price JC. Insulin regulation of glucose transport and phosphorylation in skeletal muscle assessed by PET. Am J Physiol 1999;277:E361-9.